Dose the first patient in the TYRA-200 Phase 1 clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Mar 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“TYRA expects the first patient will be dosed in this trial in the second half of 2023.”
What we found
Evidence strength A What the grades mean
The company commenced the Phase 1 clinical trial for TYRA-200 in December 2023 and confirmed the first patient was dosed, meeting the commitment to initiate the trial in the second half of 2023.
-
A Tyra Biosciences, Inc. 8-K filed 2024-03-19
“- Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 -” ✓ confirmed on the page
-
A Tyra Biosciences, Inc. 10-K filed 2024-03-19
“In December 2023, we commenced our Phase 1 clinical trial of TYRA-200” ✓ confirmed on the page
Market reaction: the shares moved +1.3% against the S&P 500 over the three sessions around the disclosure (18 Mar 2024 to 21 Mar 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 22 Mar 2023
Deadline 31 Dec 2023 (“in the second half of 2023”) · wording expected
-
Version 2 · stated 10 Aug 2023
Deadline 31 Dec 2023 (“in the second half of 2023”) · wording firm
“TYRA remains on track to dose the first patient in this trial in the second half of 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- TYRA-200 Phase 1 clinical trial first patient dose
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-TYRA-002065 · Corrections policy